UK-based speciality pharmaceuticals company Mallinckrodt is planning to invest about 144 million Canadian dollars ($107 million) in its expansion projects.
With the investments, Mallinckrodt will extend its production at four BioVectra plants in Charlottetown, Prince Edward Island, and Windsor, Nova Scotia.
Moreso, the company will get about $28 million in funding from the government to support the projects.
The projects are expected to add about 150 workers to the 300 already employed at the facilities.